Announcements

Belsomra® (suvorexant): Testing for a New Kind of Sleep Drug

08/20/2015

NMS Labs offers another unique test to assist physicians with therapeutic drug monitoring (TDM) of patients on suvorexant (Belsomra®), a sedative hypnotic indicated for the treatment of insomnia. Testing may also be helpful in detecting abuse of this schedule IV controlled substance.

4236 Suvorexant

Suvorexant is the first approved drug in its class, considered a dual orexin receptor antagonist. It blocks binding of the wake-promoting neuropeptides orexin-A and orexin-B, which are involved in facilitating wakefulness. Along with the concern for sleep driving and next-day impairment, the usual warnings for hypnotics, such as sedation, poor coordination and muscle weakness, also apply with suvorexant.

« Return to News Listing